Search "natural Ozempic" in English or Hindi and the same basket comes back: berberine capsules, myo-inositol sachets, apple cider vinegar tonics, chia "internal shower" drinks, psyllium husk shots, green tea catechin capsules and karela tablets, often bundled into a "metabolic stack" with affiliate links attached.

Almost nobody assessing these products publicly has a reason to assess them honestly, because the people with the reach are usually the people with the affiliate code. This article does the boring version instead. Each ingredient is taken on its own trial evidence: what it has actually been measured to do, how good that measurement is, what it can interact with or injure, and what Indian food and advertising law already says about how it can be sold.

• No ingredient in this category has been tested in humans the way "GLP-1 support" implies. The GLP-1 mechanism evidence comes from cell lines and rodents, not from human trials that measured GLP-1 levels and linked those measurements to appetite and weight.
• Berberine's weight effect is real and small (around 0.88 kg average in the best 2026 meta-analysis). Its drug interaction profile is the more important finding: it inhibits three key drug-processing enzymes and a drug transporter that handle a large share of common prescriptions.
• A 2025 systematic review found around one third of "natural" weight-loss products tested contained undeclared synthetic drugs, most commonly sibutramine at a median prevalence of 21.8%. A product that works better than its ingredients can explain is a reason for suspicion, not reassurance.
• Indian law already prohibits claiming a food prevents, treats or cures a disease. CDSCO advisories have specifically flagged advertising and influencer content that functions as surrogate advertising for GLP-1 medicines.
• The multi-ingredient stacks sold on marketplaces have never been tested as stacks. Safety and efficacy evidence, where it exists, applies to individual ingredients at defined doses in specific patient groups.

The category borrows its name from a prescription medicine, and the borrowed word doing the work is "GLP-1." GLP-1 is an incretin hormone released by intestinal L-cells after a meal. It raises glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and contributes to fullness. Native GLP-1 is cleared in roughly one to two minutes by the enzyme DPP-4, which is why the hormone released after a meal is a brief physiological signal rather than a sustained one.

That matters for what these products claim, because almost none of the evidence behind the GLP-1 branding is human evidence. The GLP-1 mechanism for each ingredient:

• Berberine: Effect on GLP-1 secretion shown in intestinal L-cell lines and in rodents, through pathways involving AMPK, protein kinase C and the bitter-taste receptor TAS2R38.
• Bitter melon: Incretin effect comes from mouse work only.
• Psyllium, chia, apple cider vinegar, inositols, green tea catechins: No large, well-controlled human trials have measured fasting and post-meal GLP-1 and then linked those measurements to appetite and weight over time.

Meta-analysis of soluble fibre interventions in humans has reported post-meal GLP-1 responses that were unchanged, and in some trials lower, after fibre preloads.

So the honest statement about the GLP-1 claim is not that it has been disproved. It is that for this whole ingredient set it has not been tested in people in the way the marketing implies. What has been tested, in most cases, is weight, waist and glucose, and those results are set out below.

Berberine is an isoquinoline alkaloid extracted from several plants, studied mainly for effects on glucose and lipid metabolism, with proposed action through AMPK activation, gut microbiota and bile-acid signalling.

What the weight evidence shows:

• A 2026 systematic review of 23 randomised trials found berberine reduced body weight by 0.88 kg on average, BMI by 0.48 kg/m² and waist circumference by 1.32 cm against control, with waist-hip ratio unchanged.
• Earlier meta-analyses landed in the same territory: roughly 0.8 to 2.1 kg and one to three centimetres off the waist, across trials typically running 8 to 12 weeks in people who already had type 2 diabetes, metabolic syndrome or fatty liver disease, and who were also receiving lifestyle advice.
• A separate 2026 randomised trial in 337 adults with obesity and metabolic-dysfunction-associated steatotic liver disease tested berberine 1 g a day for six months and found no significant change in visceral adipose tissue or liver fat against placebo. BMI difference: 0.02 kg/m².

Where the safety signal sits:

Berberine inhibits three drug-processing enzymes and a transporter used by many common medicines:

• CYP2D6, CYP2C9 and CYP3A4: A crossover study in healthy volunteers found berberine 300 mg three times daily for two weeks raised midazolam peak concentration and exposure by around 38 to 40%, and increased the urinary dextromethorphan ratio ninefold.
• P-glycoprotein: Pharmacokinetic work has recorded higher exposure to cyclosporine, digoxin and sirolimus when berberine is co-administered.

Those enzymes and transporters handle beta-blockers, antidepressants, antiarrhythmics, statins, benzodiazepines and immunosuppressants. Anyone already on a regular prescription who is considering berberine should raise it with the doctor who wrote that prescription, not with a seller.

Psyllium and chia work on the same principle: viscosity. Both form a gel in water, and that gel slows gastric emptying, blunts the post-meal glucose rise and increases fullness. Neither mechanism requires a hormone story to be plausible, and neither delivers the effect sizes the marketing suggests.

Psyllium: the evidence disagrees with itself

Two meta-analyses reached opposite conclusions:

• One meta-analysis of six randomised trials in 354 overweight and obese adults, using divided pre-meal doses averaging 10.8 g a day over 4.8 months, reported a 2.1 kg reduction in body weight, 0.8 kg/m² in BMI and 2.2 cm in waist circumference.
• An earlier and larger dose-response meta-analysis of 22 randomised trials found no statistically significant effect on body weight, with a mean change of −0.28 kg and a confidence interval crossing zero, and no significant effect on BMI or waist circumference.

Both figures reach this article through secondary summaries rather than the published papers, so they are reported here as an unresolved disagreement rather than a settled number.

Chia: small effects, mostly non-significant

• A six-month double-blind trial in 77 overweight or obese adults with type 2 diabetes added chia at 30 g per 1,000 kcal a day to a calorie-restricted diet and found greater weight loss than an oat-bran control: 1.9 kg against 0.3 kg, with a larger waist reduction and lower C-reactive protein.
• A separate 12-week trial using 35 g a day of chia flour recorded within-group falls of roughly 1.1 kg and 1.9 cm, but the differences against placebo were not statistically significant.
• A 2024 systematic review of 14 trials in 835 participants found improvements in blood lipids and blood pressure, some benefit on obesity indicators, and no significant linear relationship between higher chia intake and weight change per additional 10 g a day.

The mechanical risk the recipe videos leave out:

Because these fibres swell rapidly on contact with water, taking them without enough fluid carries documented risks:

• Case reports of incomplete intestinal obstruction requiring hospital care.
• Oesophageal bezoars and acute oesophageal obstruction needing endoscopic removal, including in older adults and a patient with Parkinson's disease.

Chia carries the same risk if dry seeds are swallowed and expand in the oesophagus. Pre-soaking and adequate fluid are the standing advice. Anyone with a stricture, a motility disorder or altered gut anatomy after surgery is in the group these case reports came from.

Apple cider vinegar has the most interesting trial file in this basket and the least standardised product. The evidence:

• A 2024 double-blind randomised trial in 120 overweight and obese Lebanese adolescents and young adults gave 5 to 15 mL a day of 5% vinegar diluted in water for 12 weeks and reported dose-dependent falls in body weight of around 6 to 8 kg and in BMI of 2.7 to 3.0 points against placebo, with improvements in fasting glucose, triglycerides and cholesterol. That is a large result from a single trial in one country and one narrow age band, and it has not been reproduced at that magnitude elsewhere.
• A 12-week Iranian trial pairing 30 mL a day with calorie restriction found greater reductions in weight, BMI, hip circumference and appetite scores than calorie restriction alone.
• A 2025 systematic review pooling 10 trials in 789 participants concluded that daily intake, typically around 30 mL a day for up to 12 weeks, reduced body weight, BMI and waist circumference in overweight, obese or type 2 diabetic adults. Long-term data do not exist.

The harm profile is straightforward and physical:

Vinegar sits at a pH of roughly 3 to 4. What that means in practice:

• Laboratory immersion work shows cumulative enamel and dentin loss with acidic exposure.
• A published case series described oesophageal injury from apple cider vinegar tablets, alongside wide variability in the tablets' acidity, composition and labelling.
• Delayed gastric emptying is a problem rather than a feature for anyone with gastroparesis.
• Very high intakes have been linked to low potassium.

Where safe-use advice exists it converges on 15 to 30 mL a day, always diluted in water, never as an undiluted shot.

These three share a pattern. Each has a legitimate evidence base for something, and the "natural Ozempic" framing moves it somewhere it has not been tested.

Myo-inositol and D-chiro-inositol:

These are insulin-signalling second messengers. Their action is on insulin signalling, not on GLP-1 secretion. In a Kolkata randomised trial in 140 overweight women with PCOS, myo-inositol 550 mg plus D-chiro-inositol 13.8 mg twice daily over six months produced significant reductions in BMI, waist-hip ratio, diastolic blood pressure and fasting blood sugar at three and six months against myo-inositol alone. That is a finding in insulin-resistant PCOS, at a defined dose, under supervision. Whether it transfers to an otherwise healthy adult buying a sachet on a marketplace has not been studied, and PCOS itself varies enough between people that even within the condition the answer is not uniform, as the differences between PCOS phenotypes make clear.

Green tea catechins (EGCG):

• These raise energy expenditure and fat oxidation modestly through sympathetic activation and COMT inhibition.
• An early meta-analysis of 11 trials put the average weight difference at about 1.3 kg.
• A Cochrane review of green tea preparations concluded the weight loss was around 1 kg, not statistically significant, and unlikely to matter clinically on its own.
• A 2024 review of green tea added to exercise, against exercise alone, found small statistically significant differences in weight and BMI that still sat below thresholds treated as clinically meaningful.
• High-dose extracts have been linked to rare serious liver injury and have drawn regulatory cautions in some jurisdictions. Brewed tea delivers far lower catechin concentrations than a capsule does.

Bitter melon (karela):

• An Indian trial in 75 people with type 2 diabetes added 1 to 1.5 g a day of Momordica charantia tablets to existing oral antidiabetic therapy for eight weeks and found significant reductions in fasting and post-meal glucose, HbA1c, total cholesterol and LDL, with BMI falling modestly in one dose group.
• A review of 13 trials in 892 participants reached the same place: glucose and HbA1c move, BMI data are limited and small where reported.
• Isolated hypoglycaemia has been reported when karela is combined with diabetes medication.

Across this category the more serious risk is not the listed ingredient. A 2025 systematic review and meta-analysis of laboratory testing of "natural" weight-loss products found that around one third contained undeclared synthetic drugs, with sibutramine the most frequent adulterant at a median prevalence of 21.8% across products tested. Other adulterants found included:

• Phentermine
• The antidepressant fluoxetine
• Diuretics, laxatives and stimulants

All of those carry cardiovascular or psychiatric risk and none appears on a label.

Indian sampling within that review was limited, so the contamination rate in products sold through Indian marketplaces is not known. Cross-border e-commerce means the relevant supply is not only domestic.

A product that works noticeably better than its ingredient list can explain is a reason for suspicion rather than reassurance.

What FSSAI health supplements regulations say:

Under the FSSAI health supplements and nutraceuticals regulations, health supplements are foods intended to supplement the normal diet using concentrated sources of nutrients or botanicals with an established nutritional or beneficial physiological effect. The regulations state plainly that they are not drugs. Nutrient levels generally may not exceed ICMR recommended daily allowances.

What labelling and advertising are prohibited from claiming:

Labelling, presentation and advertising may not claim that the product prevents, treats or cures a human disease, or refer to such properties. Disease risk-reduction or novel health claims need prior FSSAI approval backed by adequate scientific evidence. Where a brand name uses a descriptor such as "natural," the label must carry a disclaimer that the term is fanciful and does not describe the true nature of the product. The Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 separately prohibits advertising that gives a false impression or makes false claims, and is routinely invoked against misleading slimming advertising. Very-low-energy diets for weight reduction sit in a separate category and are to be used under medical supervision.

What enforcement looks like in practice:

ASCI's 2025 to 2026 complaints reporting puts digital media at over 97% of advertising violations, with healthcare and food among the worst sectors. Upheld cases include:

• A meal-replacement shake advertising a specific kilogram target within a month, found unsubstantiated.
• A herbal capsule advertising weight reduction without any change in lifestyle, found unsubstantiated.
• A weight-management brand claiming to be India's trusted weight-loss partner, required to modify the campaign.

Separately, a CDSCO advisory reported in March 2026 directed the industry to stop disease-awareness campaigns, digital outreach and influencer content that function as surrogate advertising for GLP-1 prescription medicines. That advisory targets pharmaceutical companies rather than food sellers, but it describes the regulatory climate into which a food product named after a prescription drug is now walking.

The useful test is not whether an ingredient does anything. Several of these do something measurable. The test is whether what it does matches what is being claimed, in people like you, at the dose in the bottle, for longer than three months, and whether the seller has told you what it interacts with.

On that test the category performs poorly:

• Short trials: Most ran for 8 to 12 weeks, with no long-term data.
• Wrong population: Most were run in people who already had diabetes, PCOS or fatty liver, not in otherwise healthy adults buying a stack online.
• Unstudied stacks: The multi-ingredient stacks actually sold have never been studied as stacks.
• Hidden safety findings: The strongest safety findings (drug interactions and adulteration data) are the ones least likely to appear in a product video.

If you are taking regular medication, the interaction question belongs with your prescribing doctor before anything else.

Taking a supplement that interacts with a regular prescription? A Voy clinician can review your full medication and supplement list. Book an assessment.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.